skip to content
home ver. 2.3. site index contact us
Schering-Plough
About Us Products and Care R&D Partnerships News and Media Investor Relations Corporate Responsibility Careers
Message from the CEO
How We Work
History of Schering-Plough
Management Team
Schering-Plough Worldwide
Speeches & Presentations
The Schering-Plough Foundation
Diversity & Inclusion
Supplier Registration
Diversity Colleague Demographics

Management Biographies

BRENT SAUNDERS
Senior Vice President and President, Consumer Health Care

Schering-Plough Corporation
Kenilworth, New Jersey

Brent Saunders is senior vice president and president, Consumer Health Care, for Schering-Plough Corporation. The Consumer Health Care segment develops, manufactures and markets OTC brands such as CLARITIN, AFRIN and CORICIDIN, and foot care and sun care products that are sold primarily in North America. He also oversees the new HomeAgain Proactive Pet Recovery Network.

Saunders joined Schering-Plough as senior vice president, Global Compliance and Business Practices, in November 2003. He is responsible for leading the U.S. and Canadian Consumer Health Care division and works collaboratively with the Global Pharmaceutical Business unit. He also is continuing in his leadership role for the new HomeAgain business.

Saunders came to Schering-Plough from PricewaterhouseCoopers, where he led the firm's compliance business advisory services group. Previously, he served as chief compliance officer for Coventry Health Care, a nationwide managed care organization, and for Thomas Jefferson University and Health System, a major academic medical center in Philadelphia.

Saunders also has extensive experience negotiating and implementing corporate integrity agreements with state and federal agencies. He is past-president and co-founder of the Health Care Compliance Association, which named him 1997 Compliance Officer of the Year.

Saunders is a noted speaker on compliance and risk management issues in the health care industry and also taught health law at Widener School of Law as an adjunct faculty member.

Saunders earned a J.D. degree from the Temple University School of Law and an M.B.A. degree from the Temple University School of Business and Management. He graduated with a B.A. degree in economics from the University of Pittsburgh.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.


 

 

Spotlight On

Combination Brochure

Brochure on the Combination

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
HomeAbout UsProducts & CareR&DPartnerships
News & MediaInvestor RelationsCorporate ResponsibilityCareers
Contact Us Site Index
© 2003 - 2008 Schering-Plough Corporation.
Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough